Wedbush restated their outperform rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a report released on Thursday morning, The Fly reports. They currently have a $64.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $42.00.

Several other research firms have also issued reports on JUNO. Vetr raised Juno Therapeutics from a hold rating to a buy rating and set a $28.85 target price for the company in a report on Monday, July 17th. Zacks Investment Research raised Juno Therapeutics from a hold rating to a buy rating and set a $32.00 target price for the company in a report on Tuesday, July 11th. BidaskClub lowered Juno Therapeutics from a strong-buy rating to a buy rating in a report on Tuesday, July 11th. Maxim Group reaffirmed a buy rating and issued a $56.00 target price (up from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Finally, Cowen and Company reaffirmed a buy rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $44.20.

Shares of Juno Therapeutics (JUNO) traded down $1.76 on Thursday, reaching $56.72. The company’s stock had a trading volume of 1,435,783 shares, compared to its average volume of 2,170,000. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics has a 1 year low of $17.52 and a 1 year high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) EPS. analysts expect that Juno Therapeutics will post -3.62 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Receives Outperform Rating from Wedbush” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-receives-outperform-rating-from-wedbush/1683353.html.

In related news, EVP Robert Azelby sold 12,869 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total value of $514,116.55. Following the transaction, the executive vice president now owns 50,289 shares in the company, valued at $2,009,045.55. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,670 shares of company stock worth $3,553,777. 15.26% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. Utah Retirement Systems lifted its stake in Juno Therapeutics by 1.8% in the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 200 shares during the last quarter. State of Wisconsin Investment Board lifted its stake in Juno Therapeutics by 1.7% in the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the last quarter. Aperio Group LLC lifted its stake in Juno Therapeutics by 4.2% in the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,194 shares during the last quarter. Finally, Amalgamated Bank lifted its stake in Juno Therapeutics by 19.0% in the second quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 1,741 shares during the last quarter. Institutional investors and hedge funds own 67.12% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

The Fly

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.